ImpediMed

ImpediMed Long-term Debt

The Long-Term Debt of ImpediMed (IPD.AX) as of Nov 6, 2026 is 16.09 M AUD. In the previous year, Long-Term Debt was 14.23 M AUD — a change of 13.09% (higher).

Long-term Debt

16.09 MAUD

YoY

13.09%

Last updated:

Long-Term Debt of ImpediMed is 2026 16.09 M AUD. Long-Term Debt of ImpediMed was 2025 14.23 M AUD. It decreases by 13.09% higher compared to the previous year.

The ImpediMed Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2019
0.00 AUD
Jan 1, 2020
507,000.00 AUD
Jan 1, 2021
159,000.00 AUD
Jan 1, 2022
0.00 AUD
Jan 1, 2023
1.15 M AUD
Jan 1, 2024
810,000.00 AUD
Jan 1, 2025
14.23 M AUD
Jan 1, 2026
16.09 M AUD
The ImpediMed Long-term Debt history
YEARLong-term DebtYoY
16.09 MAUD+13.09%
14.23 MAUD+1,656.17%
810,000.00AUD-29.38%
1.15 MAUD—
0.00AUD-100.00%
159,000.00AUD-68.64%
507,000.00AUD—
0.00AUD—
0.00AUD—
0.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Long-Term Debt of ImpediMed is 16.09 M AUD in 2026.

Long-Term Debt of ImpediMed changed from 14.23 M AUD to 16.09 M AUD, representing a 13.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt ImpediMed since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's ImpediMed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ImpediMed

All Key Metrics — ImpediMed